Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 22, 2009 - Issue 2
Submit an article Journal homepage
114
Views
2
CrossRef citations to date
0
Altmetric
From the Editor

Facts and Ideas from Anywhere

William Clifford Roberts
, MD
Pages 178-187 | Published online: 11 Dec 2017

  • Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285 (13): 1711–1718.
  • Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361 (9374): 2005–2016.
  • Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361 (9364): 1149–1158.
  • Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350 (15): 1495–1504.
  • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364 (9435): 685–696.
  • de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292 (11): 1307–1316.
  • LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352 (14): 1425–1435.
  • Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294 (19): 2437–2445.
  • Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355 (6): 549–559.
  • Rosseb⊘ AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359 (13): 1343–1356.
  • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359 (21): 2195–2207.
  • Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357 (9256): 577–581.
  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352 (1): 29–38.
  • Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295 (13): 1556–1565.
  • Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297 (12): 1344–1353.
  • Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358 (14): 1431–1443.
  • Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008;299 (14): 1678–1689.
  • Musunuru K, Blumenthal RS. Another perspective on ENHANCE: what was not discussed and communicated. Cardiology 2008;37 (4): 14–17.
  • Adams SL. ENHANCE panel advises cardiologists to use statins, scale back ezetimibe use. CardiologyToday.com 2008(May);10. Available at http://www.cardiologytoday.com/view.aspx?rid=29546; accessed February 17, 2009.
  • Mitka M. Cholesterol drug controversy continues. JAMA 2008;299 (19): 2266.
  • Davidson MH. Interpreting the ENHANCE trial. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med 2008;75 (7): 479–482, 486–488, 490–491.
  • Steinberg D. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;359 (5): 529–533.
  • O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc 2008;83 (8): 867–869.
  • Toth PP, Maki KC. A commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial: Should ezetimibe move to the “back of the line” as a therapy for dyslipidemia? J Clin Lipidol 2008;2 (5): 313–317.
  • Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359 (13): 1357–1366.
  • U.S. Food and Drug Administration. Follow-up to the January 25, 2008 early communication about an ongoing data review for ezetimibe/simvastatin (marketed as Vytorin), ezetimibe (marketed as Zetia), and simvastatin (marketed as Zocor). Available at http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin200901.htm; accessed February 17, 2009.
  • Who should take a statin? New York Times, November 17, 2008.
  • Parker-Pope T. A call for caution in the rush to statins. New York Times, November 17, 2008.
  • Sternberg S. That bad cholesterol just got worse. USA Today, February 2, 2009.
  • Park A. America's health checkup. Time, December 1, 2008.
  • Mills N, Brunner K, eds. The New Killing Fields—Massacre and the Politics of Intervention. New York: Basic Books, 2002 (276 pp.).
  • Power S. Raising the cost of genocide. In Mills N, Brunner K, eds. The New Killing Fields—Massacre and the Politics of Intervention. New York: Basic Books, 2002: 245–264.
  • Goldstone L. The Anatomy of Deception. New York: Delacorte Press Book, Bantam Dell, 2008 (342 pp.).
  • Ulin D. Is reading really making a comeback in the U.S.? Dallas Morning News, January 17, 2009.
  • Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S, Barrett-Connor E, Bhargava SK, Birgisdottir BE, Carlsson S, de Rooij SR, Dyck RF, Eriksson JG, Falkner B, Fall C, Forsén T, Grill V, Gudnason V, Hulman S, Hyppönen E, Jeffreys M, Lawlor DA, Leon DA, Minami J, Mishra G, Osmond C, Power C, Rich-Edwards JW, Roseboom TJ, Sachdev HS, Syddall H, Thorsdottir I, Vanhala M, Wadsworth M, Yarbrough DE. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 2008;300 (24): 2886–2897.
  • Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360 (2): 129–139.
  • It's a bird, it's a plane, it's an issue. Dallas Morning News, January 18, 2009.
  • Levin A. Airlines record safest 2 years. No one killed in crash of a U.S. flight. USA Today, January 12, 2009.
  • Sherwood B. You can survive! 9 ways to stay alive when the worst happens. Parade Magazine, January 11, 2009.
  • Weise E. Earthquake deaths highest since 2004. USA Today, January 7, 2009.
  • Flick D. As the year's end looms, it's a busy time at hospitals' delivery rooms. Dallas Morning News, December 31, 2008.
  • Harris S. Graduates report higher debt, primary care interest. AAMC Reporter, December 2008. Available at http://www.aamc.org/newsroom/reporter/dec08/graduates.htm; accessed February 17, 2009.
  • Deep throat's passing. The Courier-Journal, December 23, 2008.
  • Rubin R. Octuplet birth raises questions. Fertility experts give answers to the easier ones. USA Today, February 3, 2009.
  • Surdin A. Octuplets' mom waits to tell her side as criticism mounts. Dallas Morning News, February 5, 2009.
  • Goodman E. The insanity of the Suleman fourteen. Dallas Morning News, February 7, 2009.
  • Healy B. Flesh, not canvas: self-expression through body art has its drawbacks. U.S. News & World Report, February 2009.
  • Kristof N. The miracle cola diet. Dallas Morning News, December 20, 2008.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.